< Return to TrialNet E-News Main
TrialNet Expands Screening with
TrialNet must screen more than 20,000 relatives of people with type 1 diabetes each year in order to find enough candidates to reach its research goals. That’s why we are always working to find ways to make screening more accessible.
Previously, those interested in screening would need to complete the consent process in person or by mail. With the introduction of online consent, there is now another option. Individuals can confirm their eligibility and complete the necessary consent documents online. When completed, TrialNet will send them a test kit to take to a local medical lab for a blood sample. The sample is sent to TrialNet’s central lab for testing. Results are reported in about 6 weeks.
People whose results are positive for autoantibodies associated with the development of type 1 diabetes will be contacted by a TrialNet research staff member to review the results. They may be asked to have more tests at a TrialNet study center. If eligible, they will be invited to join a study aimed at preventing or delaying the disease. Annual retesting is highly encouraged for children under age 18 whose results come back negative.
No matter which method is used, screening is secure, confidential, and offered at no charge.
“By making it easier to get screened, we hope to find more people who are at risk and new ways to delay or prevent type 1 diabetes,” -TrialNet TrialNet Study Chair Jay Skyler, M.D.
For more details about the Pathway to Prevention Study: